Immatics N.V. Ordinary Shares (IMTX) Dividend History

Company News

• TCR Therapy Clinical Trial Pipeline Accelerates as 80+ Pharma Companies Rigorously Developing Drugs for the Market Entry | DelveInsight

  The T-cell receptor (TCR) therapy pipeline is rapidly expanding, with over 80 pharmaceutical companies actively developing more than 100 TCR therapies for various cancers, including solid tumors. Several promising pipeline candidates are in different stages of clinical trials, showcasing the potential of TCR therapy to revolutionize cancer treatment.

  GlobeNewswire Inc.

  Featured Companies: TCRX
• Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME

  Immatics announced positive clinical data for its TCR-T therapy candidates targeting PRAME, a protein frequently expressed in solid cancers. The data showed deep and durable responses in heavily pretreated patients, supporting the advancement of these therapies into late-stage development.

  GlobeNewswire Inc.
• Immatics Announces Pricing of $150 Million Public Offering

  Immatics, a clinical-stage biopharmaceutical company, announced the pricing of its $150 million public offering of 16,250,000 ordinary shares at $9.25 per share. The offering is expected to close on October 15, 2024.

  GlobeNewswire Inc.
• Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024

  Immatics, a clinical-stage biopharmaceutical company, announced upcoming oral and poster presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024. The presentations will focus on their TCR-T therapies targeting the PRAME antigen for the treatment of solid cancers.

  GlobeNewswire Inc.
• Immatics Announces Second Quarter 2024 Financial Results and Business Update

  Immatics reported positive clinical data for its ACTengine® IMA203 targeting PRAME in metastatic melanoma patients, with a 55% confirmed objective response rate and a favorable tolerability profile. The company also announced upcoming data presentations for its TCR Bispecifics pipeline, including IMA401 and IMA402, and the appointment of Alise Reicin, M.D. to its Board of Directors.

  GlobeNewswire Inc.